Chemed price target raised to $370 from $340 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Chemed to $370 from $340 as he moves valuations to 2020 estimates following quarterly results. The analyst reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.